NCT03528642 2026-03-17
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
18 trialsNCT02959463 2026-03-06
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04522336 2026-03-05
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03514069 2026-02-19
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04391049 2026-01-30
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinâ„¢ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
Phase 1 Active not recruiting
NCT04523818 2026-01-14
Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05236036 2026-01-14
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT06105918 2025-12-09
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Emory University
Phase 1 Active not recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT02595879 2025-11-13
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03228537 2025-11-10
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02626312 2025-10-14
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03535350 2025-09-30
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04460937 2025-07-08
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04047706 2025-06-29
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT03044613 2025-03-06
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT03132922 2024-01-22
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
Phase 1 Active not recruiting